Search alternatives:
59 a » 19 a (Expand Search)
9 a » 19 a (Expand Search)
decrease » increase (Expand Search)
Showing 1 - 20 results of 572 for search '(( 5 ppm decrease ) OR ((((( 59 a decrease ) OR ( 9 a decrease ))) OR ( _ e decrease ))))*', query time: 0.18s Refine Results
  1. 1
  2. 2

    Effect of clinical hyperthyroidism and hypothyroidism on patent diabetes. 59 cases by Hirbli, K.

    Published 1983
    “…Following treatment of the hyperthyroidism, control was improved in 63%, with an 11-83% (mean 44%) decrease in insulin dosage in 59% of them. Insulin therapy could be withdrawn in only one of the 32 insulin-treated patients. …”
    Get full text
    Get full text
    Get full text
    article
  3. 3

    Hypoxic Stress Induces Complement-Mediated Lysis of Mesenchymal Stem Cells by Downregulating Factor H and CD59 by Ramada R. Khaswaneh (22224544)

    Published 2024
    “…The level of complement system related factors; Factor H, CD59, C3b, iC3b, C5b, C9, and the complement membrane attack complex (MAC) were analyzed using Elisa assays, western blotting, and immunocytochemistry.…”
  4. 4
  5. 5

    Genetic Deletion of DNAJB3 Using CRISPR-Cas9, Produced Discordant Phenotypes by Shadi Nejat (19457212)

    Published 2023
    “…Three DNAJB3 knockout (KO) lines were generated (KO 30, 44 and 47), using CRISPR-Cas9. Male and female KO and WT mice were fed a HF diet (45% kcal fat) for 16 weeks. …”
  6. 6

    Decreased methylglyoxal-mediated protein glycation in the healthy aging mouse model of ectopic expression of UCP1 in skeletal muscle by Jinit, Masania

    Published 2023
    “…This may be achieved by decreasing protein glycation by the reactive metabolite, methylglyoxal (MG). …”
    Get full text
    Get full text
    Get full text
    article
  7. 7

    Decreased methylglyoxal-mediated protein glycation in the healthy aging mouse model of ectopic expression of UCP1 in skeletal muscle by Jinit Masania (7164239)

    Published 2023
    “…This may be achieved by decreasing protein glycation by the reactive metabolite, methylglyoxal (MG). …”
  8. 8

    A slow but steady nanoLuc: R162A mutation results in a decreased, but stable, nanoLuc activity by Wesam S. Ahmed (10170053)

    Published 2024
    “…In this regard, engineering of brighter bioluminescent proteins, i.e. luciferases, has played a significant role. …”
  9. 9
  10. 10
  11. 11

    Durability of Cardiometabolic Outcomes Among Adolescents After Sleeve Gastrectomy: First Study with 9-Year Follow-up by Wahiba Elhag (5245547)

    Published 2022
    “…The preoperative mean body mass index (BMI) (45.60 ± 6.50 kg/m2) decreased at year 1 (30.04 ± 4.96 kg/m2, P=0.001) and was maintained up to 9 years (30.20 ± 3.92 kg/m2, P = 0.001). …”
  12. 12

    eIF4A inhibition prevents the onset of cytokine-induced muscle wasting by blocking the STAT3 and iNOS pathways by Zvi Cramer (10742876)

    Published 2018
    “…Here we show that hippuristanol, a compound that impedes eIF4A in a manner distinct from PatA, similarly inhibits the iNOS/NO pathway and cytokine-induced muscle wasting. …”
  13. 13

    Effects of vitamin E derivatives on the proliferation of KG-1 leukemic cells in vitro by Rizk, Sandra

    Published 2017
    “…XTT cell viability assay, which detects the presence of metabolically active cells, was used to assess cell proliferation. A decrease in proliferation of KG-1 cells was observed upon treatment with both forms of vitamin E derivatives; however, β-T3 was more potent than γ-T3 in promoting cell death with lower IC50 values. …”
    Get full text
    Get full text
    Get full text
    article
  14. 14

    Sleeve Gastrectomy in Patients with Type 2 Diabetes: Anthropometric and Cardiometabolic Improvements at 1, 3, 5, 7, and 9 years—Are the Initial Benefits Sustained? by Wahiba Elhag (5245547)

    Published 2025
    “…Postoperatively, there was a significant and sustained weight reduction, amounting to a mean decrease of 9 kg/m<sup>2</sup> in BMI at year 9 and associated excess weight loss between 59%<sub>year</sub> 1 and 46%<sub>year</sub> 9. …”
  15. 15

    Soluble Neuropilin-1 Response to Hypoglycemia in Type 2 Diabetes: Increased Risk or Protection in SARS-CoV-2 Infection? by Abu Saleh Md Moin (6189512)

    Published 2021
    “…However, 4-hours post-hypoglycemia, sNRP1, VEGF and ADAM9 were elevated in T2D(p<0.05). SEMA3A was not different at baseline; at hypoglycemia, SEMA3A decreased in controls only. …”
  16. 16

    LDL-C Targets in Secondary Prevention: How Low Should We Go? by Karim Bayoumy (3496688)

    Published 2019
    “…The concern for adverse effects with very low LDL-C levels is not backed by the literature, and side effects appear to be medication-specific. There still remains a question of the cost-effectiveness of some non-statin therapies particularly PCSK9 inhibitors, in spite of recent price decreases, and whether the benefit is worth the cost.…”
  17. 17

    Nebulized fentanyl for respiratory symptoms in patients with COVID-19 (ventanyl trial) by Nissar Shaikh (11659441)

    Published 2022
    “…The proposed theory behind that was that fentanyl decreased the rate of spontaneous respiratory rate, diminished the brain stem chemoreceptor response to hypoxia and hypercarbia, in addition to exhibiting a modulating effect on the brain stem. …”
  18. 18

    Addressing Challenges of Distance Learning in the Pandemic with Edge Intelligence Enabled Multicast and Caching Solution by Kashif Bilal (16896357)

    Published 2022
    “…Due to the closure of educational institutes, work and learn from home methods have burdened the network resources and considerably decreased a viewer’s Quality of Experience (QoE). The situation calls for innovative techniques to handle the surging load of video traffic on cellular networks. …”
  19. 19
  20. 20

    Therapeutic targeting of the TPX2/TTK network in colorectal cancer by Hibah Shaath (5599658)

    Published 2023
    “…<h3>Background</h3><p dir="ltr">While the increased screening, changes in lifestyle, and recent advances in treatment regimen have decreased colorectal cancer (CRC) mortality, metastatic disease and recurrence remains a major clinical challenge. …”